Document Detail

Effect of the specific cholecystokinin-receptor antagonist loxiglumide on bombesin stimulated pancreatic enzyme secretion in man.
MedLine Citation:
PMID:  1714084     Owner:  NLM     Status:  MEDLINE    
We have investigated the effects of the specific cholecystokinin (CCK) receptor antagonist loxiglumide on basal and bombesin stimulated pancreatic enzyme secretion, bilirubin output and plasma CCK release in six healthy subjects. The data were compared with those obtained in control experiments where saline was infused instead of loxiglumide. Basal amylase output (4.7 +/- 0.8 kU/45 min), trypsin output (2.9 +/- 0.8 kU/45 min) and bilirubin output (7.7 +/- 2.8 mmol/45 min) gradually declined during infusion of loxiglumide to values of 1.3 +/- 0.3 kU/45 min, 0.5 +/- 0.1 kU/45 min and 0.4 +/- 0.0 mmol/45 min, respectively, reaching statistical significance (P less than 0.05) in the 30 to 45-min period after the start of the loxiglumide infusion. In the control experiments saline infusion failed to influence basal amylase, trypsin and bilirubin output, while bombesin stimulated amylase output from 4.7 +/- 0.8 kU/45 min to 25.1 +/- 5.1 kU/45 min (P less than 0.05), trypsin output from 2.9 +/- 0.8 kU/45 min to 11.6 +/- 2.0 kU/45 min (P less than 0.05) and bilirubin output from 7.7 +/- 2.8 mmol/45 min to 68.0 +/- 16.0 mmol/45 min (P less than 0.05). Loxiglumide failed to significantly influence bombesin stimulated amylase output (36.7 +/- 9.0 kU/45 min) and trypsin output (8.3 +/- 2.9 kU/45 min), but almost abolished bilirubin output (9.7 +/- 3.6 mmol/45 min) (P less than 0.05). Basal plasma CCK (2.4 +/- 0.1 pM) was not significantly influenced by loxiglumide (2.4 +/- 0.2 pM).(ABSTRACT TRUNCATED AT 250 WORDS)
M C Jebbink; J B Jansen; D M Mooy; L C Rovati; C B Lamers
Related Documents :
23875614 - Clinical applications of exercise stress echocardiography in the treadmill with upright...
9860784 - Prognostic value of treadmill exercise testing: a population-based study in olmsted cou...
24282574 - Long-term exercise is a potent trigger for Δfosb induction in the hippocampus along the...
20643664 - The impact of acute reduction of continuous-flow left ventricular assist device support...
10227674 - Stereological estimation of the volume weighted mean volumes of alveoli and acinar path...
24509984 - Familiarisation to and reproducibility of cycling at 110% peak power output.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Regulatory peptides     Volume:  32     ISSN:  0167-0115     ISO Abbreviation:  Regul. Pept.     Publication Date:  1991 Feb 
Date Detail:
Created Date:  1991-09-11     Completed Date:  1991-09-11     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8100479     Medline TA:  Regul Pept     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  361-8     Citation Subset:  IM    
Department of Gastroenterology and Hepatology, University Hospital, Leiden, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amylases / metabolism
Bilirubin / metabolism
Bombesin / pharmacology*
Cholecystokinin / blood*
Duodenum / drug effects,  enzymology
Pancreas / drug effects,  enzymology*
Proglumide / analogs & derivatives*,  pharmacology
Receptors, Cholecystokinin / drug effects*
Reg. No./Substance:
0/Receptors, Cholecystokinin; 107097-80-3/loxiglumide; 31362-50-2/Bombesin; 635-65-4/Bilirubin; 6620-60-6/Proglumide; 9011-97-6/Cholecystokinin; EC 3.2.1.-/Amylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intraoperative brachytherapy alone for incomplete resected recurrent rectal cancer.
Next Document:  Galanin induces contraction of isolated cells from circular muscle layer of pig ileum.